Tafenoquine interim data presentation scheduled
60 Degrees Pharmaceuticals plans to present interim data on tafenoquine for severe babesiosis. The event is scheduled for October 6, 2026, and marks a key regulatory milestone for the company.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed